Bioalmanac
Orforglipron
Foundayo (brand) · LY3502970
The first GLP-1 pill that is a true small molecule. Approved in April 2026, and taken any time of day with no food or water restrictions.
Storage
- Freeze-dried powder
- Tablets at room temperature, in the original packaging.
- After mixing
- Not applicable. This is a tablet.
Dose ranges reported in sources
Descriptions of what sources report, not recommendations.
| Goal | Range | Frequency | Source |
|---|---|---|---|
| Approved escalation for weight management | 6000–36000 mcg | Once daily, escalating over several months | Clinical trial |
When to stop
- Severe, persistent abdominal pain, particularly radiating to the back. Possible pancreatitis. Seek urgent care.
- Pain in the upper right abdomen, fever, or yellowing of the skin or eyes.
- A lump in the neck, hoarseness that does not resolve, or difficulty swallowing.
- Vomiting severe enough that you cannot keep fluids down.
- Any allergic response: rash, hives, facial swelling or difficulty breathing. Seek urgent care.
Use your browser’s print dialog and choose “Save as PDF”. This block is hidden when printed.